Delivery Order SPE2DB22D2206-SPE2DB24FFB37
- Not listed
- This federal contract award is valued at $56,788.50 and was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order for the delivery of Pfizer COVID-19 vaccine doses during the 2024-2025 period, with an ultimate completion date of November 15, 2024. This contract is not designated with a set-aside requirement. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the...
- This federal contract award is a delivery order worth $1,642.75 issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The award is for the provision of Pfizer COVID-19 vaccines between 2024-2025, with an ultimate completion date of November 7, 2024. The contract is a firm fixed-price arrangement with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the...
- This federal contract award, valued at $1,135.77, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Pfizer COVID-19 vaccines. The contract has an ultimate completion date of September 27, 2024 and is a Firm Fixed Price Delivery Order. It is not designated as a set-aside contract. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
- This federal contract award, valued at $1,100.15, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Pfizer COVID-19 vaccine doses, with a period of performance from May 2024 to May 2025. The contract is a firm fixed-price delivery order and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
- This federal contract award is for a delivery order worth $1,081.34 awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the supply of Pfizer's COVID-19 vaccine, including 0.9 ML doses, from June 2023 to February 2024. The contract has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that serves as a key vendor for federal healthcare programs,...
- This federal contract award is for the delivery of Pfizer's COVID-19 vaccine over a period of 6 months to 4 years, under an Emergency Use Authorization. The $2,259.62 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen has a significant Indefinite Delivery Contract...
- This federal contract award is for the delivery of Pfizer COVID-19 vaccine doses to the Defense Logistics Agency (DLA) Troop Support Medical. The $1,642.75 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, on October 22, 2024. The contract has an ultimate completion date of November 13, 2024 and does not have a set-aside designation. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $2,259.62, is for the delivery of 0.9 mL doses of the Pfizer COVID-19 vaccine, with a period of performance from November 2024 to December 2024. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA, which provides...
- This federal contract award, valued at $2,200.30, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Pfizer COVID-19 vaccines with a period of performance running through March 2025. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and covering a comprehensive...
- This contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the procurement of Pfizer COVID-19 vaccines. The contract has a ceiling value of $1,129.80 and a completion date of February 19, 2025. It is a delivery order contract with a firm fixed price pricing type. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB24FFB37Delivery Order
This federal contract award, valued at $7,569.38, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The current delivery order, with an ultimate completion date of January 16, 2024, is for Pfizer COVID-19 vaccines (0.9 mL) to be provided from June 2023 to June 2024. The contract has no set-aside designation, indicating open competition. Amerisourcebergen's parent company, Cencora, Inc., also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 1/12/24 |